Table 3 Effect size estimates of pneumococcal (SP) conjugate vaccines (PCV) on childhood meningitis mortality for inclusion in LiST. (A) Approximated using evidence from existing reviews and can be edited by the LiST user [1]. (B) Approximated from the proportion of invasive pneumococcal disease caused by vaccine serotypes in the existing 10-valent PCV from an existing review and can be edited by the LiST user [17]. (C) Estimate of the effectiveness of PCV against vaccine-serotype SP meningitis mortality (risk ratio) from this review. (D) Effect size for PCV on meningitis mortality for LiST calculated by multiplying (A) x (B) x (C). (E) Uncertainty bounds.
| 听 | Proportion of all-cause meningitis mortality due to SP [1, 18] (A) | Proportion of SP meningitis caused by vaccine serotypes (B) | Effectiveness of PCV against vaccine-type SP meningitis mortality (C) | Effect size for PCV on meningitis mortality (A x B x C) = (D) | Uncertainty bounds (E) |
|---|---|---|---|---|---|
African meningitis belt | 0.46 (0.42-0.50) | 0.72 (0.67-0.76) | 0.84 (0.00-0.98) | 0.28 | 0.05-0.30 |
Africa non-meningitis belt | 0.52 (0.47-0.58) | 0.72 (0.67-0.76) | 0.84 (0.00-0.98) | 0.32 | 0.05-0.34 |
Asia | 0.52 (0.47-0.58) | 0.70 (0.64-0.75) | 0.84 (0.00-0.98) | 0.31 | 0.05-0.33 |
Europe | 0.52 (0.47-0.58) | 0.81 (0.78-0.82) | 0.84 (0.00-0.98) | 0.35 | 0.06-0.38 |
Latin America and Caribbean | 0.52 (0.47-0.58) | 0.77 (0.74-0.80) | 0.84 (0.00-0.98) | 0.34 | 0.06-0.36 |
Oceania | 0.52 (0.47-0.58) | 0.75 (0.63-0.84) | 0.84 (0.00-0.98) | 0.33 | 0.06-0.35 |